Soil Component Analysis.

a<p>% weight of whole SLS.</p>b<p>clay classification.</p>c<p>% of total clay weight.</p>d<p>clay weight % of total.</p>e<p>electrical conductivity (EC), measurement of salinity.</p>f<p>NA, not applicable.</p

Disease status and detection of prions in non-clinical mice inoculated with Mte-treated-inocula.

<p>Disease status and detection of prions in non-clinical mice inoculated with Mte-treated-inocula.</p

Incidence and infectivity titers of prion inocula before and after adsorption.

a<p>number of terminally ill mice/number infected.</p>b<p>DPI, days post infection.</p>c<p>×10⁴ mean LD₅₀ after 24 h @ 23°C. All SDs ≤0.001×10^4.</p>d<p>Initial titer of inocula prior to adsorption.</p>e<p>NA, not applicable.</p>f<p>below linear range of bioassay.</p

Representative Histology of TgA20 indicator mice.

<p>Selected examples of histological analysis using immunohistochemistry with PrP specific BAR224 Ab (reddish-brown staining, panels A–F) and anti-GFAP antibody staining activated astrocytes (bright red, panels G–L) in hippocampal sections. (<b>A and G</b>) Negative control sections from mice inoculated with SLS-treated NBH exhibited no PrP^Sc staining or spongiosis and limited astrocyte activation. (<b>B and H</b>) Positive control sections from mice inoculated with RML5 revealed diffuse PrP^Sc staining and significant spongiosis and astrogliosis. (<b>C and I</b>) Sections from mice inoculated with SLS-treated TgA20RML resulted in limited PrP^Sc deposits, spongiosis and astrogliosis, while (<b>D and J</b>) sections from mice inoculated with Mte-treated TgA20RML revealed little or no scrapie neuropathology. (<b>E and K</b>) sections from mice inoculated with SLS-treated RML5 resulted in neuropathology similar to sections from TgA20RML treated mice (Band H). (<b>F and L</b>) Hippocampal sections from the only mouse to become ill with Mte treated RML5 showed limited PrP^Sc spongiosis and astrogliosis.</p